As reflected by TIMER analysis, MTHFD2 expression was considerably augmented in multiple types of cancers, like BLCA, breast cancer, cholangiocarcinoma, colon adenocarcinoma, and kidney renal clear cell carcinoma (Fig. 1A). This evidence concerns the gene MTHFD2 and breast carcinoma.